NEWPORT BEACH, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it expects the European Medicines Agency (EMA) Committee for Medicinal Products for

First Peer-Reviewed Publication from TRANSPARENCY Global Clinical Program Further Validates Safety and Efficacy of Jeuveau™ vs Placebo NEWPORT BEACH, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on

Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8 th , 2019 in New York, NY NEWPORT BEACH, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc.

Provides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau™ U.S. Launch NEWPORT BEACH, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced

IRVINE, Calif. , March 15, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release fourth quarter and full year 2018 financial results and provide a business

NEWPORT BEACH, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment of Crystal Muilenburg as Vice President, Corporate Communications & Public Relations .  “Crystal brings a

Conference Call Scheduled for at 8:00am ET / 5:00am PT NEWPORT BEACH, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), today announced that members of management will host a conference call today, February 4 th , 2019, at 8:00 a.m. ET / 5:00 a.m.

Jeuveau™ is the first aesthetic-only neurotoxin approved in the U.S. – launch planned Spring 2019 Global clinical program in 2,100 subjects, known as TRANSPARENCY, included two Phase III U.S. trials, the largest head-to-head aesthetic pivotal trial versus Botox® and two long-term safety studies